<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<doc>
  <docno>
    <textblock>FR940118-0-00019</textblock>
  </docno>
  <parent>
    <textblock>FR940118-0-00004</textblock>
  </parent>
  <text>
    <textblock>§4.115b</textblock>
    <textblock>Ratings of the genitourinary system_diagnoses.</textblock>
  </text>
  <table>
    <textblock>␣</textblock>
    <textblock>1␣</textblock>
    <textblock>1Rating</textblock>
    <textblock>7500␣Kidney, removal of one:</textblock>
    <textblock>Minimum evaluation</textblock>
    <textblock>30</textblock>
    <textblock>Or rate as renal dysfunction if there is nephritis, infection, or pathology of the other.</textblock>
    <textblock>7501␣Kidney, abscess of:</textblock>
    <textblock>Rate as urinary tract infection</textblock>
    <textblock>30</textblock>
    <textblock>7502␣Nephritis, chronic:</textblock>
    <textblock>Rate as renal dysfunction.</textblock>
    <textblock>7504␣Pyelonephritis, chronic:</textblock>
    <textblock>Rate as renal dysfunction or urinary tract infection, whichever is predominant.</textblock>
    <textblock>7505␣Kidney, tuberculosis of:</textblock>
    <textblock>Rate in accordance with §§4.88b or 4.89, whichever is appropriate.</textblock>
    <textblock>7507␣Nephrosclerosis, arteriolar:</textblock>
    <textblock>Rate according to predominant symptoms as renal dysfunction, hypertension or heart disease. If rated under the cardiovascular schedule, however, the percentage rating which would otherwise be assigned will be elevated to the next higher evaluation.</textblock>
    <textblock>7508␣Nephrolithiasis:</textblock>
    <textblock>Rate as hydronephrosis,</textblock>
    <textblock>except for</textblock>
    <textblock>recurrent stone formation requiring one or more of the following:</textblock>
    <textblock>1. diet therapy</textblock>
    <textblock>2. drug therapy</textblock>
    <textblock>3. invasive or non-invasive procedures more than two times/year</textblock>
    <textblock>30</textblock>
    <textblock>7509␣Hydronephrosis:</textblock>
    <textblock>Severe; Rate as renal dysfunction.</textblock>
    <textblock>Frequent attacks of colic with infection (pyonephrosis), kidney function impaired</textblock>
    <textblock>30</textblock>
    <textblock>Frequent attacks of colic, requiring catheter drainage</textblock>
    <textblock>20</textblock>
    <textblock>Only an occasional attack of colic, not infected and not requiring catheter drainage</textblock>
    <textblock>10</textblock>
    <textblock>7510␣Ureterolithiasis:</textblock>
    <textblock>Rate as hydronephrosis,</textblock>
    <textblock>except for</textblock>
    <textblock>recurrent stone formation requiring one or more of the following:</textblock>
    <textblock>1. diet therapy</textblock>
    <textblock>2. drug therapy</textblock>
    <textblock>3. invasive or non-invasive procedures more than two times/year</textblock>
    <textblock>30</textblock>
    <textblock>7511␣Ureter, stricture of:</textblock>
    <textblock>Rate as hydronephrosis,</textblock>
    <textblock>except for</textblock>
    <textblock>recurrent stone formation requiring one or more of the following:</textblock>
    <textblock>1. diet therapy</textblock>
    <textblock>2. drug therapy</textblock>
    <textblock>3. invasive or non-invasive procedures more than two times/year</textblock>
    <textblock>30</textblock>
    <textblock>7512␣Cystitis, chronic, includes interstitial and all etiologies, infectious and non-infectious:</textblock>
    <textblock>Rate as voiding dysfunction.</textblock>
    <textblock>7515␣Bladder, calculus in, with symptoms interfering with function:</textblock>
    <textblock>Rate as voiding dysfunction</textblock>
    <textblock>7516␣Bladder, fistula of:</textblock>
    <textblock>Rate as voiding dysfunction or urinary tract infection, whichever is predominant.</textblock>
    <textblock>Postoperative, superapubic cystotomy</textblock>
    <textblock>100</textblock>
    <textblock>7517␣Bladder, injury of:</textblock>
    <textblock>Rate as voiding dysfunction.</textblock>
    <textblock>7518␣Urethra, stricture of:</textblock>
    <textblock>Rate as voiding dysfunction.</textblock>
    <textblock>7519␣Urethra, fistual of:</textblock>
    <textblock>Rate as voiding dysfunction.</textblock>
    <textblock>Multiple urethroperineal fistulae</textblock>
    <textblock>100</textblock>
    <textblock>7520␣Penis, removal of half or more</textblock>
    <textblock>30</textblock>
    <textblock>Or rate as voiding dysfunction.</textblock>
    <textblock>7521␣Penis removal of glans</textblock>
    <textblock>20</textblock>
    <textblock>Or rate as voiding dysfunction.</textblock>
    <textblock>7522␣Penis, deformity, with loss of erectile power</textblock>
    <textblock>20</textblock>
    <textblock>7523␣Testis, atrophy complete:</textblock>
    <textblock>Both</textblock>
    <textblock>20</textblock>
    <textblock>One</textblock>
    <textblock>0</textblock>
    <textblock>7524␣Testis, removal:</textblock>
    <textblock>Both</textblock>
    <textblock>30</textblock>
    <textblock>One</textblock>
    <textblock>0</textblock>
    <textblock>Note</textblock>
    <textblock>_In cases of the removal of one testis as the result of a service-incurred injury or disease, other than an descended or congenitally undeveloped testis, with the absence or nonfunctioning of the other testis unrelated to service, an evaluation of 30 percent will be assigned for the service-connected testicular loss. Testis, undescended, or congenitally undeveloped is not a ratable disability.</textblock>
    <textblock>7525␣Epididymo-orchitis, chronic only:</textblock>
    <textblock>Rate as urinary tract infection.</textblock>
    <textblock>For tubercular infections: Rate in accordance with §§4.88b or 4.89, whichever is appropriate.</textblock>
    <textblock>7527␣Prostate gland injuries, infections, hypertrophy, postoperative residuals:</textblock>
    <textblock>Rate as voiding dysfunction or urinary tract infection, whichever is predominant.</textblock>
    <textblock>7528␣Malignant neoplasms of the genitourinary system</textblock>
    <textblock>100</textblock>
    <textblock>Note</textblock>
    <textblock>_Following the cessation of surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure, the rating of 100 percent shall continue with a mandatory VA examination at the expiration of six months. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local reoccurrence or metastasis, rate on residuals as voiding dysfunction or renal dysfunction, whichever is predominant.</textblock>
    <textblock>7529␣Benign neoplasms of the genitourinary system:</textblock>
    <textblock>Rate as voiding dysfunction or renal dysfunction, whichever is predominant.</textblock>
    <textblock>7530␣Chronic renal disease requiring regular dialysis:</textblock>
    <textblock>Rate as renal dysfunction.</textblock>
    <textblock>7531␣Kidney transplant:</textblock>
    <textblock>Following transplant surgery</textblock>
    <textblock>100</textblock>
    <textblock>Thereafter: Rate on residuals as renal dysfunction, minimum rating</textblock>
    <textblock>30</textblock>
    <textblock>Note</textblock>
    <textblock>_The 100 percent evaluation shall be assigned as of the date of hospital admission for transplant surgery and shall continue with a mandatory VA examination one year following hospital discharge. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter.</textblock>
    <textblock>7532␣Renal tubular disorders (such as renal glycosurias, aminoacidurias, renal tubular acidosis, Fanconi's syndrome, Bartter's syndrome, related disorders of Henle's loop and proximal or distal nephron function, etc.):</textblock>
    <textblock>Minimum rating for symptomatic condition</textblock>
    <textblock>20</textblock>
    <textblock>Or rate as renal dysfunction.</textblock>
    <textblock>7533␣Cystic diseases of the kidneys (polycystic disease, uremic medullary cystic disease, Medullary sponge kidney, and similar conditions):</textblock>
    <textblock>Rate as renal dysfunction.</textblock>
    <textblock>7534␣Atherosclerotic renal disease (renal artery stenosis or atheroembolic renal disease):</textblock>
    <textblock>Rate as renal dysfunction.</textblock>
    <textblock>7535␣Toxic nephropathy (antibotics, radiocontrast agents, nonsteroidal anti-inflammatory agents, heavy metals, and similar agents):</textblock>
    <textblock>Rate as renal dysfunction.</textblock>
    <textblock>7536␣Glomerulonephritis:</textblock>
    <textblock>Rate as renal dysfunction.</textblock>
    <textblock>7537␣Interstitial nephritis:</textblock>
    <textblock>Rate as renal dysfunction.</textblock>
    <textblock>7538␣Papillary necrosis:</textblock>
    <textblock>Rate as renal dysfunction.</textblock>
    <textblock>7539␣Renal amyloid disease:</textblock>
    <textblock>Rate as renal dysfunction.</textblock>
    <textblock>7540␣Disseminated intravascular coagulation with renal cortical necrosis:</textblock>
    <textblock>Rate as renal dysfunction.</textblock>
    <textblock>7541␣Renal involvement in diabetes mellitus, sickle cell anemia, systemic lupus erythematosus, vasculitis, or other systemic disease processes.</textblock>
    <textblock>Rate as renal dysfunction.</textblock>
    <textblock>7542␣Neurogenic bladder:</textblock>
    <textblock>Rate as voiding dysfunction.</textblock>
  </table>
  <frfiling>
    <textblock>[FR Doc. 94-1045 Filed 1-14-94; 8:45 am]</textblock>
  </frfiling>
  <billing>
    <textblock>BILLING CODE 8320-01-P</textblock>
  </billing>
</doc>
